Parabilis Medicines, Inc.
Research Parabilis Medicines, Inc. (PBLS) on Bullrun: market cap USD 3.42B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPBLS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.42B
- Financial periodQ2 2026
- RevenueUSD 148.00K
- Net income-USD 52.46M
- Free cash flow-USD 4.24M
Valuation Snapshot
latest market cap is USD 3.42B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 145.89M | -USD 124.02M | n/a | -1.81 | USD 27.71M | USD 58.70M | -USD 16.52M |
| FY2024 | USD 0 | -USD 117.91M | -USD 104.49M | n/a | -2.01 | USD 47.28M | USD 66.20M | USD 56.44M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 3.42B | n/a | n/a | n/a |
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Parabilis Medicines, Inc.'s market cap?
Parabilis Medicines, Inc.'s market capitalization is USD 3.42B.
What does Parabilis Medicines, Inc. do?
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment.